Quality ID #262: Image Confirmation of Successful Excision of Image-Localized Breast Lesion National Quality Strategy Domain: Patient Safety

Similar documents
Measure #262: Image Confirmation of Successful Excision of Image-Localized Breast Lesion National Quality Strategy Domain: Patient Safety

Quality ID #409: Clinical Outcome Post Endovascular Stroke Treatment National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

DENOMINATOR: All final reports for patients, regardless of age, undergoing a CT procedure

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DESCRIPTION: Percentage of patients aged 2 years and older with a diagnosis of AOE who were not prescribed systemic antimicrobial therapy

Quality ID #145: Radiology: Exposure Dose or Time Reported for Procedures Using Fluoroscopy National Quality Strategy Domain: Patient Safety

General Radiology Improvement Database

experienced. focused. evolving. just like you.

Setting The study setting was secondary care. The economic study was carried out in the USA.

STEPS TO APPLY FOR A NOVEL CPT CODE

G8876 DOCUMENTATION OF REASON(S) FOR NOT PERFORMING MINIMALLY INVASIVE BIOPSY TO DIAGNOSE BREAST CANCER PREOPERATIVELY (E.G

Digital breast tomosynthesis-guided biopsy: preliminary experience

Breast Biopsy. Breast Tissue Markers. Cassi II. Beacon. Cassi Star Breast Tissue Marker with exceptional visualisation

Vacuum-Assisted Ultrasound excision of a breast lesion

Section A: Case Study: Integration of CPT Codes into the Breast and Cervical Cancer Project (BCCP) System at the Cuyahoga County Board of Health

Surgical/Cytology Specimen Collection and Handling

FRIENDS OF AMIGO. Advanced Multimodality Image Guided Operating Suite

Computer-Aided Surgical Navigation Coding Guide Neurosurgery. May 1, 2009

CANDIDATE PERFORMANCE MEASURE INFORMATION

Intravascular Ultrasonic Probe Imaging During Core Biopsy Procedures. University of Wisconsin-Madison College of Engineering BME 201 March 12, 2004

Ultrasound guided biopsy using magnetic resonance volume navigation for the histological approach of additional breast lesions: a new technique

Press. Innovative systems for radiology from Siemens. Healthcare Erlangen, March 3, ECR 2016 in Vienna: Hall X5, Booth 12

A step by step guide to stereotactic - vacuum assisted breast biopsy

MultiCare Platinum & StereoLoc II Prone and Upright Stereotactic Biopsy Solutions

3/6/2017 TOMOSYNTHESIS GUIDED BREAST BIOPSY LEARNING OBJECTIVES DISCLOSURES

Investor Relations Hologic

SEGMENTATION, CO-REGISTRATION, AND CORRELATION OF OPTICAL COHERENCE TOMOGRAPHY AND X-RAY IMAGES FOR BREAST CANCER DIAGNOSTICS JONATHAN SUN THESIS

BME101 Introduction to Biomedical Engineering Medical Imaging Özlem BİRGÜL Ankara University Department of Biomedical Engineering

BEYOND WIRES. Overcoming the Challenges of Breast Tumor Localization. Charles Cox, MD Pat Whitworth, MD Kate Maguire. Published by

Introduction. FDA Approval. Breast Tomosynthesis From the Ground Up

Radiography Curriculum Analysis

Radiofrequency Identification Tags for Preoperative Tumor Localization: Proof of Concept

RADIATION ONCOLOGY RESIDENCY PROGRAM Competency Evaluation of Resident

Integrated Radiology & Pathology Diagnostic Services: The Time is Now at UCLA

Occams Business Research & Consultancy

Micro Calcifications Detection for Breast Cancer Diagnosis using Infrared Thermal Imaging Apparatus

Core Biopsy of the Breast Lesions: Review of Technical Problems and Solutions: A Pictorial Review

Translational Multimodality Optical Imaging

AVANCE SUBPROYECT FILE

Biomedical Imaging Modalities

HOLOGIC products available from ALKO Enterprises, Inc.

Fast and flexible. syngo MammoReport. Answers for life.

A COMPREHENSIVE FRAMEWORK FOR IMAGE GUIDED BREAST SURGERY. Rebekah H. Conley. Thesis. Submitted to the Faculty of the

3D Spherical Harmonics Deformation Visualization of Intraoperative Organ

MRI Systems Market to 2018

QNX Solution for Medical Market Kosuke Abe, APAC Sales Team. QNX Software Systems Limited

Resona 6. New Waves in Ultrasound Innovation. Premium Ultrasound System

i n t e r v e n t i o n a l b r e a s t b i o p s y s o l u t i o n s The Right Biopsy Solution for every patient

Errata and Technical Corrections CPT 2015 Date: November 11, 2014

TITLE: Fluorescence and Diffuse Reflectance Spectroscopy for Breast Cancer Diagnosis During Core Needle Biopsy

Ultrasound Bi-dimensional Navigation Technology for Breast application

Radiology Student Projects Catalog

Diagnosis for Open Wounds as a Result of Cancer Resection

ORDER ENTRY IN RADIOLOGY

LOGIQ S8 with XDclear Simply Amazing

Accepted Manuscript. Tag, You re It! Finding and Treating Early Lung Cancers in a Single Setting. Ngoc-Quynh Chu, MD, Yolonda L.

How GE Research Developed MRI (Magnetic Resonance Imaging) Guided Surgery By Kirby Vosburgh

2017 Eleview BILLING AND CODING GUIDE

PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)

United States Patent Fulton, III et al.

Clinical Trials. Understanding. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation

Histology mimicking phantoms for the high-frequency ultrasound of breast cancer surgical margins: Comparison between gelatin and agarose media

CT to Ultrasound Registration: A Porcine Phantom Study. J. Xiang, S. Gill, C. Nguan, P. Abolmaesumi and R. N. Rohling University of British Columbia

Risk Mitigation in Breast Predictive Factor Testing. Elizabeth H Hammond MD

Data Collection and Aggregation: Making It Work for Your P4P Program

Spiculated Lesions and Architectural Distortions Detection in Digital Breast Tomosynthesis Datasets

Deliverable 2.1: Definition of paradigms representing exemplary breast lesions cases

Ultrasound and Photoacoustics

Knight Cancer Institute Cancer Early Detection Advanced Research Center (CEDAR) Call for Clinical Matched Case Control Sample Collection

The Next Revolution in Endoscopic Ultrasound Guided Biopsy Products

Magnetic Resonance Imaging-guided Breast Biopsies: Tips and Tricks

Data Mining for Genomic- Phenomic Correlations

MEDICAL IMAGING - GLOBAL MARKET FOR DISPLAYS AND POST-PROCESSING SOFTWARE

SOLUTIONS Express Enterprise SP Enterprise XP Integral Breast Workspace. better images mean better results

IMPROVING THE ACCURACY OF DIAGNOSTIC BREAST ULTRASOUND

Errata and Technical Corrections CPT 2015 Date: July 10, 2015

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

CHAP3-CPTcodes _final doc Revision Date: 1/1/2018

Effectiveness of hemostasis with Foley catheter after vacuumassisted

CHAP3-CPTcodes _final docx Revision Date: 1/1/2019

LOMISA HEALTHCARE. BRIEF PRESENTATION By José Ramón Sánchez - Director, LOMISA HEALTHCARE

Medical instrumentationi 11/19/2010

Comprehensive Solutions

2111: ALL Post-HCT. Add/ Remove/ Modify. Manual Section. Date. Description. Comprehensive Disease- Specific Manuals


PRESENT ON ADMISSION (POA)

Retinoblastoma Genetic Test Submission Guide

MEANINGFUL USE CRITERIA PHYSICIANS

American College of Radiology Detailed Summary of the CY 2017 Final Rule for the Hospital Outpatient Prospective Payment System

Innovation Process in Medical Imaging

Premium Performance. Extraordinary Technology.

Accuracy Evaluation of a 3D Ultrasound-guided Biopsy System

Innovative Medical Products. General Imaging CT and MRI Breast Biopsy Radiation Therapy Mammography

Considerations for Choosing MIPS Quality Measures. July 2017

ANTHEM BLUE CROSS REIMBURSEMENT POLICIES AND MCKESSON CLAIMSXTEN RULES

Urology Equipment & Accessories

Re: Medicare Program; Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Proposed Rule; CMS-1656-P

HOSPITAL OUTPATIENT BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)

Transcription:

Quality ID #262: Image Confirmation of Successful Excision of Image-Localized Breast Lesion National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Image confirmation of lesion(s) targeted for image guided excisional biopsy or image guided partial mastectomy in patients with nonpalpable, image-detected breast lesion(s). Lesions may include: microcalcifications, mammographic or sonographic mass or architectural distortion, focal suspicious abnormalities on magnetic resonance imaging (MRI) or other breast imaging amenable to localization such as positron emission tomography (PET) mammography, or a biopsy marker demarcating site of confirmed pathology as established by previous core biopsy INSTRUCTIONS: This measure is to be submitted each time an image guided excisional biopsy or wire localized partial mastectomy is performed in patients with non-palpable, image-detected breast lesions. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measurespecific denominator coding. Measure Submission: The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry submissions; however, these codes may be submitted for those registries that utilize claims data. DENOMINATOR: Number of patients aged 18 years and older on date of encounter with non-palpable, image-detected (by mammogram, ultrasound, or breast MRI, PET mammography or other imaging modality) breast lesion requiring localization of lesion (benign or malignant) for targeted resection (either excisional biopsy or partial mastectomy) Denominator Criteria (Eligible Cases): Patients aged 18 years on date on encounter AND Diagnosis for Breast Lesion (ICD-10-CM): C50.011, C50.012, C50.019, C50.021, C50.022, C50.029, C50.111, C50.112, C50.119, C50.121, C50.122, C50.129, C50.211, C50.212, C50.219, C50.221, C50.222, C50.229, C50.311, C50.312, C50.319, C50.321, C50.322, C50.329, C50.411, C50.412, C50.419, C50.421, C50.422, C50.429, C50.511, C50.512, C50.519, C50.521, C50.522, C50.529, C50.611, C50.612, C50.619, C50.621, C50.622, C50.629, C50.811, C50.812, C50.819, C50.821, C50.822, C50.829, C50.911, C50.912, C50.919, C50.921, C50.922, C50.929, C79.81, D05.01, D05.02, D05.11, D05.12, D24.1, D24.2, D24.9, D48.61, D48.62, D49.3, N60.01, N60.02, N60.09, N60.11, N60.12, N60.19, N60.21, N60.22, N60.29, N60.31, N60.32, N60.39, N60.41, N60.42, N60.49, N60.81, N60.82, N60.89, N60.91, N60.92, N60.99, N61.0, N61.1, N62, N63.0, N63.10, N63.11, N63.12, N63.13, N63.14, N63.20, N63.21, N63.22, N63.23, N63.24, N63.31, N63.32, N63.41, N64.0, N64.1, N64.2, N64.3, N64.4, N64.51, N64.52, N64.53, N64.59, N64.81, N64.82, N64.89, N64.9, R92.0, R92.1, R92.2, R92.8, T85.44XA, T85.44XD, T85.44XS AND Patient encounter during the performance period (CPT): 19125, 19301, 19302 AND NOT DENOMINATOR EXCLUSION: Patients with needle localization specimens which are not amenable to intraoperative imaging such as MRI needle wire localization, or targets which are tentatively identified on mammogram or ultrasound Page 1 of 5

which do not contain a biopsy marker but which can be verified on intraoperative inspection or pathology (e.g., needle biopsy site where the biopsy marker is remote from the actual biopsy site): G8873 NUMERATOR: Patients undergoing excisional biopsy or partial mastectomy of a non-palpable lesion whose excised breast tissue was evaluated by imaging (x-ray, ultrasound, MRI, PET mammography or other imaging modality) intraoperatively to confirm successful inclusion of targeted lesion OR Numerator Options: Performance Met: Performance Not Met: Excised tissue evaluated by imaging intraoperatively to confirm successful inclusion of targeted lesion (G8872) Excised tissue not evaluated by imaging intraoperatively to confirm successful inclusion of targeted lesion, reason not given (G8874) RATIONALE: Many benign breast lesions and breast cancers are image-detected and will involve some form of image localization. Specimen radiography or specimen ultrasonography should routinely be performed for all excisions of image-detected abnormalities to document success of the procedure in excising the target. CLINICAL RECOMMENDATION STATEMENTS: Specimen radiography or specimen ultrasonography should be routinely performed for all excisions of image- detected abnormalities to help document the success of the procedure in finding the target. Specimen radiography should use two 90-degree orthogonal views. (The American Society of Breast Surgeons, 2001) COPYRIGHT: This measure is owned by The American Society of Breast Surgeons. THESE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. Page 2 of 5

Page 3 of 5

2018 Registry Flow for Quality ID #262: Image Confirmation of Successful Excision of Image-Localized Breast Lesion Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in submitting this Individual Specification. This flow is for registry data submission. 1. Start with Denominator 2. Check Patient Age: a. If the Age is greater than or equal to 18 years of age on date of service and equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing. b. If the Age is greater than or equal to 18 years of age on date of service and equals Yes during the measurement period, proceed to check Patient Diagnosis. 3. Check Patient Diagnosis: a. If Diagnosis of Breast Lesion as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing. b. If Diagnosis of Breast Lesion as Listed in the Denominator equals Yes, proceed to check Encounter Performed. 4. Check Encounter Performed: a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing. b. If Encounter as Listed in the Denominator equals Yes, proceed to Denominator Exclusion. 5. Check Denominator Exclusion: a. If Denominator Exclusion as listed equals Yes, do not include in Eligible Denominator Patient Population. Stop Processing. b. If Denominator Exclusion as listed equals No, include in Eligible Population. 6. Denominator Population: a. Denominator Population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 procedures in the Sample Calculation. 7. Start Numerator 8. Check Excised Tissue Evaluated by Imaging Intraoperatively to Confirm Successful Inclusion of Targeted Lesion: a. If Excised Tissue Evaluated by Imaging Intraoperatively to Confirm Successful Inclusion of Targeted Lesion equals Yes, include in Data Completeness Met and Performance Met. b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 50 procedures in the Sample Calculation. Page 4 of 5

c. If Excised Tissue Evaluated by Imaging Intraoperatively to Confirm Successful Inclusion of Targeted Lesion equals No, proceed to Excised Tissue Not Evaluated by Imaging Intraoperatively to Confirm Successful Inclusion of Targeted Lesion Reason Not Given. 9. Check Excised Tissue Not Evaluated by Imaging Intraoperatively to Confirm Successful Inclusion of Targeted Lesion Reason Not Given: a. If Excised Tissue Not Evaluated by Imaging Intraoperatively to Confirm Successful Inclusion of Targeted Lesion. Reason Not Given equals Yes, include in the Data Completeness Met and Performance Not Met. b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 procedures in the Sample Calculation. c. If Excised Tissue Not Evaluated by Imaging Intraoperatively to Confirm Successful Inclusion of Targeted Lesion Reason Not Given equals No, proceed to Data Completeness Not Met. 10. Check Data Completeness Not Met a. If Data Completeness Not Met equals No, Quality Data Code or equivalent not submitted. 10 procedures have been subtracted from Data Completeness Numerator in the Sample Calculation. Page 5 of 5